BioXcel Therapeutics, Inc.
BTAI
$1.85
$0.169.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 366.00K | 214.00K | 1.10M | 582.00K | 376.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 366.00K | 214.00K | 1.10M | 582.00K | 376.00K |
| Cost of Revenue | 832.00K | 1.17M | 62.00K | 80.00K | 714.00K |
| Gross Profit | -466.00K | -956.00K | 1.04M | 502.00K | -338.00K |
| SG&A Expenses | 4.09M | 7.68M | 9.45M | 13.26M | 9.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.83M | 13.95M | 17.54M | 24.75M | 20.25M |
| Operating Income | -10.46M | -13.74M | -16.44M | -24.16M | -19.88M |
| Income Before Tax | -10.86M | -13.65M | -8.30M | -26.79M | -22.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.86M | -13.65M | -8.30M | -26.79M | -22.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.86M | -13.65M | -8.30M | -26.79M | -22.26M |
| EBIT | -10.46M | -13.74M | -16.44M | -24.16M | -19.88M |
| EBITDA | -10.38M | -13.66M | -16.36M | -24.09M | -19.80M |
| EPS Basic | -3.57 | -5.15 | -3.30 | -13.89 | -12.09 |
| Normalized Basic EPS | -2.23 | -2.85 | -1.85 | -8.68 | -7.56 |
| EPS Diluted | -3.57 | -5.15 | -3.30 | -13.89 | -12.09 |
| Normalized Diluted EPS | -2.23 | -2.85 | -1.85 | -8.68 | -7.56 |
| Average Basic Shares Outstanding | 3.04M | 2.65M | 2.52M | 1.93M | 1.84M |
| Average Diluted Shares Outstanding | 3.04M | 2.65M | 2.52M | 1.93M | 1.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |